Ideaya Biosciences [IDYA] vs Madrigal [MDGL] Detailed Stock Comparison
Ideaya Biosciences
NASDAQ
Loading...
Madrigal
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Ideaya Biosciences wins in 7 metrics, Madrigal wins in 10 metrics, with 0 ties. Madrigal appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Ideaya Biosciences | Madrigal | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -7.32 | -19.74 | Madrigal |
| Price-to-Book Ratio | 2.25 | 13.80 | Ideaya Biosciences |
| Debt-to-Equity Ratio | 2.77 | 17.81 | Ideaya Biosciences |
| PEG Ratio | -0.25 | 0.27 | Ideaya Biosciences |
| EV/EBITDA | -3.97 | -29.06 | Madrigal |
| Profit Margin (TTM) | 0.00% | -54.68% | Ideaya Biosciences |
| Operating Margin (TTM) | -5,488.94% | -22.18% | Madrigal |
| Return on Equity | -35.09% | -36.30% | Ideaya Biosciences |
| Return on Assets (TTM) | -23.84% | -18.31% | Madrigal |
| Free Cash Flow (TTM) | $-251.44M | $-462.03M | Ideaya Biosciences |
| 1-Year Return | -34.30% | 78.75% | Madrigal |
| Price-to-Sales Ratio (TTM) | 308.13 | 18.69 | Madrigal |
| Enterprise Value | $1.51B | $8.96B | Madrigal |
| EV/Revenue Ratio | 216.25 | 17.38 | Madrigal |
| Gross Profit Margin (TTM) | N/A | 95.74% | N/A |
| Revenue per Share (TTM) | $0 | $23 | Madrigal |
| Earnings per Share (Diluted) | $-3.84 | $-12.66 | Ideaya Biosciences |
| Beta (Stock Volatility) | 0.12 | -1.03 | Madrigal |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Ideaya Biosciences vs Madrigal Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Ideaya Biosciences | -1.28% | -9.39% | 4.32% | 10.46% | 32.31% | -2.19% |
| Madrigal | -1.65% | -0.15% | 20.40% | 45.43% | 32.05% | 37.75% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Ideaya Biosciences | -34.30% | 120.52% | 86.86% | 118.76% | 118.76% | 118.76% |
| Madrigal | 78.75% | 523.60% | 251.74% | 482.51% | 230.19% | 25.37% |
News Based Sentiment: Ideaya Biosciences vs Madrigal
Ideaya Biosciences
News based Sentiment: POSITIVE
September was a highly productive month for Ideaya Biosciences, characterized by positive clinical trial data across multiple programs (IDE397, IDE849, darovasertib), encouraging analyst coverage and price target increases, and a strong financial position. These developments collectively strengthen the investment case and suggest significant potential for future growth.
Madrigal
News based Sentiment: POSITIVE
September was a remarkably positive month for Madrigal Pharmaceuticals, driven by a massive revenue beat, a soaring stock price, and strong analyst support. The company is actively expanding its market reach, and the overall narrative points to significant growth potential, making this a highly noteworthy month for investors.
Performance & Financial Health Analysis: Ideaya Biosciences vs Madrigal
| Metric | IDYA | MDGL |
|---|---|---|
| Market Information | ||
| Market Cap | $2.16B | $9.63B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 1,684,560 | 331,490 |
| 90 Day Avg. Volume | 1,146,220 | 414,823 |
| Last Close | $24.61 | $432.22 |
| 52 Week Range | $13.45 - $37.80 | $200.63 - $457.16 |
| % from 52W High | -34.89% | -5.46% |
| All-Time High | $47.74 (Feb 12, 2024) | $457.16 (Sep 08, 2025) |
| % from All-Time High | -48.45% | -5.46% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | 13.54% |
| Quarterly Earnings Growth | N/A | 13.54% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | -0.55% |
| Operating Margin (TTM) | -54.89% | -0.22% |
| Return on Equity (TTM) | -0.35% | -0.36% |
| Debt to Equity (MRQ) | 2.77 | 17.81 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $10.95 | $31.32 |
| Cash per Share (MRQ) | $7.64 | $35.76 |
| Operating Cash Flow (TTM) | $-293,704,992 | $-307,412,992 |
| Levered Free Cash Flow (TTM) | $-188,326,256 | $-219,782,000 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Ideaya Biosciences vs Madrigal
| Metric | IDYA | MDGL |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -7.32 | -19.74 |
| Forward P/E | -9.05 | -30.96 |
| PEG Ratio | -0.25 | 0.27 |
| Price to Sales (TTM) | 308.13 | 18.69 |
| Price to Book (MRQ) | 2.25 | 13.80 |
| Market Capitalization | ||
| Market Capitalization | $2.16B | $9.63B |
| Enterprise Value | $1.51B | $8.96B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 216.25 | 17.38 |
| Enterprise to EBITDA | -3.97 | -29.06 |
| Risk & Other Metrics | ||
| Beta | 0.12 | -1.03 |
| Book Value per Share (MRQ) | $10.95 | $31.32 |
Financial Statements Comparison: Ideaya Biosciences vs Madrigal
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | IDYA | MDGL |
|---|---|---|
| Revenue/Sales | $0 | $137.25M |
| Cost of Goods Sold | N/A | $4.51M |
| Gross Profit | N/A | $132.74M |
| Research & Development | $74.23M | $44.17M |
| Operating Income (EBIT) | $-88.81M | $-79.31M |
| EBITDA | $-87.57M | $-69.56M |
| Pre-Tax Income | $-77.49M | $-73.24M |
| Income Tax | N/A | N/A |
| Net Income (Profit) | $-77.49M | $-73.24M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | IDYA | MDGL |
|---|---|---|
| Cash & Equivalents | $130.00M | $183.65M |
| Total Current Assets | $707.87M | $987.98M |
| Total Current Liabilities | $50.85M | $167.24M |
| Long-Term Debt | $25.66M | $118.76M |
| Total Shareholders Equity | $1.02B | $710.64M |
| Retained Earnings | $-695.02M | $-1.88B |
| Property, Plant & Equipment | $38.41M | $4.01M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | IDYA | MDGL |
|---|---|---|
| Operating Cash Flow | $-57.47M | $-81.76M |
| Capital Expenditures | $-1.33M | $0 |
| Free Cash Flow | $-61.67M | $-88.89M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | IDYA | MDGL |
|---|---|---|
| Shares Short | 10.09M | 4.05M |
| Short Ratio | 11.00 | 9.02 |
| Short % of Float | 0.14% | 0.21% |
| Average Daily Volume (10 Day) | 1,684,560 | 331,490 |
| Average Daily Volume (90 Day) | 1,146,220 | 414,823 |
| Shares Outstanding | 86.50M | 22.00M |
| Float Shares | 81.82M | 10.98M |
| % Held by Insiders | 0.01% | 0.08% |
| % Held by Institutions | 1.15% | 1.08% |
Dividend Analysis & Yield Comparison: Ideaya Biosciences vs Madrigal
| Metric | IDYA | MDGL |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |